E Nuff Sed

Healthcare Profits: Assessing Company Sensitivity to Obamacare

How do explain the fact that US Pharma companies spend 2 - 3 times in BME (business development, advertising, marketing and lobbying) than R&D. Look at the income statement of any big pharma.
The fact is that most drugs are me-too molecules marketed the hell out by armies of expensive sales reps.

Johnson & Johnson Steals Mentor Corp.: Who's Next?

Very good analysis. JNJ is making a huge push into "beauty" including beauty devices (fillers, implants etc. are classified as medical devices). These devices are generally immune to private label competition and depend on deep relationships with dermatologists and plastic surgeons who usually specialize in installing one set of devices (wide moat).

Methink Allergan could also be in J&J's target - it may acquire Botox and the ophthalmic business in one fell swoop. J&J currently has the biggest "OTC" ophthalmic business with the Visine brand.